Role of extracellular matrix proteins and tumor stroma in DNA repair and cancer progression
Role of extracellular matrix proteins and tumor stroma in DNA repair and cancer progression
批准号:
10331085
负责人:
Taru Eliisa Muranen
金额:
$39.23万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-02-01 至 2026-01-31
关键词:
AdhesionsBindingBiologyChemoresistanceChemosensitizationComplexDNA DamageDNA RepairDNA Repair PathwayDNA replication forkDataDrug resistanceEnvironmentEventExtracellular MatrixExtracellular Matrix ProteinsFibroblastsGenesGeneticGlucocorticoidsGoalsKnock-outLaboratory StudyLeadLinkMalignant NeoplasmsMalignant neoplasm of pancreasMediatingModelingNeoplasm MetastasisOrganoidsOutcomePTK2 genePancreatic Ductal AdenocarcinomaPathway interactionsPatientsPhosphorylationPhosphotransferasesProteinsPublic HealthRadiation therapyReportingResearchResistanceRoleSamplingSerumSignal PathwaySignal TransductionStressSurvival RateTestingTreatment EfficacyTreatment outcomeWorkadhesion receptorbasecancer cellcancer therapychemotherapyeffective therapyhomologous recombinationimprovedin vivo Modelinnovationinsightmortalitymouse modelneoplastic cellnovelpancreatic cancer modelpancreatic ductal adenocarcinoma modelpatient derived xenograft modelrefractory cancertargeted treatmenttherapy outcometherapy resistanttreatment responsetreatment strategytumortumor microenvironmenttumor progression
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
Pancreatic ductal adenocarcinoma (PDA) is the fourth lethal cancer in the U.S. with a 5-year survival rate of
only ~10%. The mainstay of therapy in PDA is chemotherapy, however, the majority of the tumors rapidly
develop treatment resistance. Therefore, a critical need exists to understand what drives the emergence of
drug resistance in PDA, and to develop better treatment strategies. One contributing factor to drug resistance
in PDA is the tumor microenvironment, which is characterized by abundant stroma, rich in extracellular matrix
(ECM) proteins, most frequently secreted by cancer-associated fibroblasts. The stroma and the secreted ECM
proteins can induce resistance towards chemotherapies, which work by inflicting DNA damage. One way for
the stroma to induce chemo-resistance would be by enhancing DNA repair. Our data show that the cancer-
associated fibroblast-secreted ECM proteins stimulate DNA repair in PDA tumor cells, making them more
resistant to treatments. The overall objective of this application is to investigate the mechanistic basis by which
the tumor microenvironment, and particularly secreted stromal and ECM proteins, stimulate DNA repair. Our
central hypothesis is that the candidate protein we have identified, called N-Myc-Downstream Regulated Gene
1 (NDRG1), conveys signals from the ECM contact to the DNA repair machinery, and our preliminary data
support this hypothesis. To test this hypothesis further, we propose the following three specific aims: 1) to
determine the detailed signaling events by which secreted ECM proteins lead to NDRG1 activation; 2) to
determine the mechanism by which NDRG1 regulates DNA repair; and 3) to assess the efficacy of NDRG1-
pathway inhibition in enhancing chemotherapy in patient-derived organoids and in vivo models of pancreatic
cancer. The research proposed here is innovative, in our opinion, because the research on chemoresistance
and DNA repair has not been studied in the context of adhesion signaling and stromal microenvironment, nor
has the protein we propose to study here, NDRG1, been linked to DNA repair. Therefore, successful
completion of this work would lead to a more complete mechanistic understanding on how tumor-stroma cross-
talk and fibroblast-secreted matrix proteins regulate DNA repair, and how NDRG1 protein contributes to DNA
repair and treatment resistance. These contributions are expected to be significant because they reveal novel
DNA repair biology that is regulated by extracellular matrix environment in one of the most lethal, stroma rich
and drug resistant cancers, and will allow us to test whether targeting this signaling pathway will enhance
chemotherapy efficacy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of extracellular matrix proteins and tumor stroma in DNA repair and cancer progression
-
批准号:10177365
-
项目类别:
-
资助金额:$39.79万
-
财政年份:2021
-
负责人:Taru Eliisa Muranen
-
依托单位:
Role of extracellular matrix proteins and tumor stroma in DNA repair and cancer progression
-
批准号:10550145
-
项目类别:
-
资助金额:$39.23万
-
财政年份:2021
-
负责人:Taru Eliisa Muranen
-
依托单位:
Mechanisms of extracellular matrix mediated drug resistance
-
批准号:8566599
-
项目类别:
-
资助金额:$10.24万
-
财政年份:2013
-
负责人:Taru Eliisa Muranen
-
依托单位:
Mechanisms of extracellular matrix mediated drug resistance
-
批准号:9353728
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2013
-
负责人:Taru Eliisa Muranen
-
依托单位:
Mechanisms of extracellular matrix mediated drug resistance
-
批准号:8712425
-
项目类别:
-
资助金额:$10.24万
-
财政年份:2013
-
负责人:Taru Eliisa Muranen
-
依托单位:
Mechanisms of extracellular matrix mediated drug resistance
-
批准号:9349842
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2013
-
负责人:Taru Eliisa Muranen
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: